Five-Year Data Confirm Lasting Benefit of Pembrolizumab Chemotherapy Combo in Cervical Cancer
Five-year results from the KEYNOTE-826 trial confirm that adding pembrolizumab to first-line chemotherapy delivers durable survival benefit for patients with ...
